Following the cashcall, Abzena can now expand its manufacturing project capacity
Showing 25 of 5433
The company, which developed and out-licensed AZD9412, believes the interferon beta candidate has potential.
Its high-value, pre-clinical portfolio has been developed to generate licensing deals
US probe sales exceeded the UK for the first time with other overseas market also going well
Concepta has said already its next development will be a monitor to measure the impact of chronic stress
Circassia booked restructuring costs and impairments of £80.0mln in 2016 leading it to report a pretax loss of £144.9mln, up from a £62.8mln loss in 2015
"We are pleased to announce the supply of LPLDL to HLH which will be sold as part of its market leading Lactobact brand," said OptiBiotix's boss, Stephen O'Hara
Belinostat was granted approval in the US in 2014, but is not yet approved in Europe.
Collagen is moving its US R&D operations from San Jose to Minneapolis, where it already has a base
Wanda has offloaded its holding in digital health platform OncoVerse to BTG plc for an undisclosed sum
He has over 35 years’ experience in the life sciences arena
“We are now focusing on our core strengths around our unique drug discovery platform and the discovery of novel preclinical drugs," said chairman Iain Ross.
Dr Gregory Brown and John Poulos bring with them a breadth and depth of industry experience
The two will work together to develop and initiate a liver cancer program testing Clevegen in clinical trials
Mediclinic expects a £12mln contribution to full year profit from its stake in Spire Healthcare
Enrico Vanni has bought another 100,000 shares at 27.5p a pop
Jan Petracek will fill the void left by Neil Clark, chief executive of Ergomed’s PrimeVigilance subsidiary, who is moving to Destiny Pharma
Data will be presented to a host of industry professionals at the event in Amsterdam
Collagen presented a poster at the Society for Biomaterials annual meeting in Minneapolis over the weekend
It has found a specialist outsourced sales group that will target the 64 hospitals on the island.
Bracknor is to convert another £100,000 worth of loan notes at a conversion price of 27.89p
Stifel has repeated a 'buy' rating on Amryt Pharma as the company makes progress in developing drugs for the treatment of rare and orphan diseases
Louise Makin, BTG’s CEO, said: "Our business has performed well this year. We have made significant progress in executing our strategy to become a leading provider of Interventional Medicine therapies.”
It formerly held just under 42% of the healthcare products business, which has raised £2.25mln from the float and has a market capitalisation of £8.25mln.
The Paris-based group is pioneering the use of hafnium oxide nanoparticles to boost the effectiveness of radiotherapy